Guse Kyle 4

What Happened
Kyle Guse, a director of PLUS Therapeutics (PSTV), had 922 restricted stock units (RSUs) vest and convert into 922 shares of common stock on July 1, 2026. The conversion/exercise was reported at a $0.00 price, so no cash was paid or received; the filing shows the derivative units were converted to common shares rather than a sale.

Key Details

• Transaction date: 2026-07-01. Transaction code M (exercise/conversion of a derivative).
• Shares acquired: 922 common shares; price per share reported $0.00; total cash exchanged $0.
• Disposition entry also shows the derivative units (922 RSUs) were converted/settled (no sale of shares reported).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 = each RSU represents a contingent right to one share; F2 = this represents vesting under an RSU grant that vests in four substantially equal quarterly installments beginning July 1, 2026.
• Filing timeliness: filing date equals the report period (2026-07-01); no late filing indicated in the excerpt.

Context
This was a vesting/conversion of RSUs (a routine equity compensation event), not an open-market purchase or sale. Because the shares were converted from RSUs and not immediately sold, this action does not by itself signal a buy or sell decision by the director.